focus gilead sciences annual report gilead sciences annual report gilead sciences inc lakeside drive foster city california gilead sciences biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need companys mission advance care patients suffering lifethreatening diseases worldwide headquartered foster city california gilead operations north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead sciences gilead logo design hepsera letairis ranexa truvada viread vistide volibris registered trademarks gilead sciences inc one related companies atripla registered trademark bristolmyers squibb gilead sciences llc lexiscan registered trademark astellas us llc tamiflu registered f trademark hoffmannla roche inc macugen registered trademark eyetech inc wwwgileadcom full us prescribing information gilead products available wwwgileadcomour focus organization individuals working sites countries around world together share one common focus advancing discovery development delivery new medications people worldwide silvia pictured cover annual report living hiv since story one many inspire us adrian ray phd principal scientist drug metabolism swami swaminathan phd vice president structural chemistry dedicated researchers gilead helping advance therapy hivaids lifethreatening conditions fs nosellot ngised gilead gilead derek spencer ms cnrp executive director jacques initiative institute human virology university maryland school medicine derek spencer nurse practitioner baltimore native recognized providing comprehensive care engaging community confronting hivrelated stigma could help address epidemic city derek colleagues established jacques initiative multidisciplinary holistic healthcare program focuses integrating outreach screening linkage care treatment retention gileads work lab clinic helped create treatment options patients healthcare professionals like derek hongmei mo md director biology gilead sciences transforming treatment forging partnerships first single tablet regimen hiv atripla introduced working develop effective alloral regimen collaborations kinds across departments gilead therapeutic areas oncology example initiated multi helped transform treatment disease one pill require burdensome interferon injections external partners enhance ability develop year research agreement yale university search patients take hiv medications dose deliver new products multiple therapeutic areas whether genetic basis underlying molecular mechanisms several formulation experts like mark lauren apply scientific increase convenience could reduce risk resistance lab field crossfunctional teams work together forms cancer investment earlystage research today expertise challenging process combining multiple medica develop one component multidrug regimen innovate aspects business gileads chemistry holds potential yield urgently needed targeted cancer tions single tablet work part gileads ongoing missed five years later introduced second single tablet biology teams work side side sharing information among labs treatments future effort make safe effective medicines simple take regimen complera working toward approval across hallways identify design new molecules richard p lifton md phd sterling professor genetics internal third antiretroviral product quad mark menning senior research scientist formulation process development medicine chairman department genetics yale university director yale center gilead sciences lauren wiser research scientist formulation process work external organizations advance research human genetics genomics investigator howard hughes medical institute concept complete regimen oncedaily tablet also development gilead sciences development manufacture products tim pigot senior director marketing gilead sciences louisa leung associate longterm goal treatment hepatitis c director market access reimbursement gilead sciences expanding access staying connected recognize many people might benefit hiv focus program works make hiv screening among employees hiv therapeutic specialist marta helps providers understand profile role gileads therapies may yet diagnosed medical care able routine urban communities across united states reaches medical professionals eastern europe products feedback receives ongoing afford treatments help change gilead supports screening developing world international access program one gileads newest locations warsaw gileads needs patients helps inform shape gileads educa initiatives provides assistance programs help patients provides hiv treatment million people growing team european region generates nearly tional programs around world access medications steep discounts mid announced fiveyear percent companys annual revenues marta debniaklatuszynska therapeutic specialist gilead sciences donation ambisome world health organization took immediate action growing wait lists marta meets providers regularly discuss therapeutic treat patients visceral leishmaniasis one us aids drug assistance programs jeopardized patients access advances field hiv information shares deadliest parasitic diseases hiv medicines around country instituting additional mother child uganda dayansky anez gloria lamprea nurse rebates antiretroviral products also expanded urban health plan huy pham manager manufacturing gilead sciences gilead silvia hiv advocate silvia born rome italy youngest family four years old diagnosed hiv remembers time one fear isolation london lives silvia introduced network hivpositive women whose support encouragement helped appreciate inner strength today silvia works local advocacy organization positively uk helping hivpositive women men find voices lets let hiv limit us support treatment care live lives dignity achieve dreams silvia marks gileads th anniversary stockholders confident innovation integrity hard work allow us make employees friends great progress years come john c martin phd chairman chief executive officer past year one exciting focus science periods gileads nearly year history gilead pursues science goal transforming closed annual revenues treatment lifethreatening diseases research billion commercial products ro development effort largest ever bust pipeline across therapeutic areas phase clinical studies evalu ating compounds potential become diverse experiences backgrounds per next generation innovative therapies hiv hepa titis serious respiratory cardiovascular metabolic spectives contributions employees conditions cancer inflammation come many different forms supporting discovery new compounds designing clini november announced acquisition cal trials enhancing manufacturing processes pharmasset brought us gs oral preparing regulatory submissions oversee hepatitis c compound phase clinical trials expands existing hepatitis c pipeline goal ing commercial launch new products transform standard care patients individually employees focus achieving hepatitis c delivering alloral regimen elimi excellence designated roles together nates need weekly injections interferon share one focus acquisition pharmasset significantly accelerated pace could deliver goal bring new medications areas un integrated gs phase studies met medical need patients around world rd program left right kevin young cbe executive vice president commercial operations robin l washington senior vice president chief financial officer norbert w bischofberger phd executive vice president research development chief scientific officer john c martin phd chairman chief executive officer saw record revenues atripla truvada ranexa letairis cayston ambisome gregg h alton executive vice president corporate medical affairs kristen metza senior vice president human resources john f milligan phd president chief operating officer important new datasets emerged define clinical profile marketed products investigational compounds acquisitions calistoga pharmaceuticals inc august us food drug administra also made important progress year inves potential use truvada prevent infection arresto biosciences inc addition research tion fda approved complera second single tigational agent gs novel prodrug tenofovir atrisk hivnegative individuals approach known partnership yale solid foundation tablet regimen hiv addition product much smaller dose could enable single tablet preexposure prophylaxis prep based oncology gs enter phase trials approved europe eviplera november regimens hiv drugs currently possible results several multinational studies conducted gs evaluated three phase midst launching regimen could include regimens developed gilead government academic institutions gilead sub studies myelofibrosis pancreatic cancer colon several european countries products collaboration companies mitted regulatory filing fda december cancer recent purchase biologics manufac example november announced partnership approval oncedaily truvada reduce risk turing facility oceanside california brings us new additionally completed several phase studies develop single tablet regimen combining janssens hiv infection among uninfected adults expertise antibody manufacturing support hiv helped advance new oncedaily single darunavir emtriva gs cobicistat ability produce clinical supplies gs tablet regimens october november field chronic hepatitis b virus hbv infec potential future product candidates part filed us european approval quad piv may landmark study known hptn tion important fiveyear data presented late nership yale focused helping us discover otal trials product enrolled patients provided additional evidence antiretroviral therapy showing viread treatment lead new targets cancer therapy scientists work took place sites across four continents role treating hiv also pre reduction liver fibrosis reversal cirrhosis together search genetic basis underlying teams worked diligently complete studies venting transmission results showed hivinfected affecting million people worldwide molecular mechanisms many forms cancer submitted quad data us regulatory authorities people began treatment immediately chronic hbv remains significant global challenge record time six weeks last patient visit percent less likely transmit virus uninfected focus treatment comprising four components viread emtriva partners compared delayed starting treat cardiovascular disease investigating truvada boosting agent cobicistat ment data prompted many public health expanded use ranexa established therapy important new datasets emerged integrase inhibitor elvitegravir quad single tablet experts call universal offer treatment stable chronic angina november define clinical profile marketed regimen first contain integrase inhibitor people hiv immediately upon diagnosis initiated multicountry phase trial partner products investigational compounds preparing launch product united local health departments adopted ship cardiovascular research foundation states third quarter policy additionally new data emerged regarding evaluate ranexa angina patients incomplete august us fda approved complera second single tablet regimen hiv gilead focused pursuing science goal transforming treatment lifethreatening diseases gilead access program reaches million developing world patients representing onequarter patients hiv treatment worldwide revascularization following percutaneous coronary inter reducing burden obtaining test results prior threequarters patients access program endemic areas developing world ambisome vention pci patient population risk repeat given monthly prescription following taking generic versions gilead products produced commercially available years hospitalization procedures study change letairis sales increased percent indian manufacturing partners july continues address significant unmet medical determine whether addition ranexa standard expanded agreements indian needs systemic fungal infections result therapy reduces rate major adverse cardiovas finally initiated phase study evaluate partners include future rights manufacture dedicated efforts team europe beyond cular events addition evaluating whether cystic fibrosis cf therapy cayston treatment pipeline products including quad upon regula ambisome revenues grew percent ranexa may used treat patients coro infections noncf bronchiectasis obstructive tory approval expanded agreements also permit million worldwide nary artery disease diabetes define lung disease airways become damaged due first time sale generic viread potential benefit initiated first phase study infection leading poor airflow preliminary results treatment hepatitis b also july gilead became united states continue support ranexa january type diabetes expected first company join medicines patent pool patient assistance programs provide medicines organization established facilitate expanded across therapeutic areas cost lowincome focused efforts employees across organiza focus access access hiv treatment developing world uninsured patients copay assistance program tions research commercial drug safety regulatory sharing patents help unable afford insurance copays medical affairs teams helped us achieve important important us developing new products milestone letairis treatment pulmonary help fight neglected tropical disease visceral focus results ensuring products available patients arterial hypertension march fda agreed leishmaniasis vl made product donation worth need gilead access program remove boxed warning potential risk reaches million developing world million world health organization gilead generated product sales liver injury letairis based collection patients representing onequarter patients december vl affects half million billion percent increase patient years postmarketing data well hiv treatment worldwide people year left untreated almost always majority revenue driven continuing data collected gileads labsync program fatal gilead providing nearly successes atripla truvada mostpre change means letairis patients longer vials ambisome five years treat scribed hiv regimen product respectively required undergo monthly liver monitoring patients support vl control efforts united states major european countries achieved record market share combined hiv portfolio well cardiopulmonary products gilead products available countries around world financial highlights product sales total revenues millions millions ranexa letairis ambisome antiviral franchise cardiovascular respiratory products also pro thank employees reaching millions vided larger percentage revenues ever people worldwide lifesaving medicines increase percent marks gileads th anniversary confident innovation integrity hard would like acknowledge guidance work allow us make great progress earnings per share operating cash flow board directors members scien years come thank continued millions tific medical advisory boards provided support gilead sciences expertise helped us achieve accomplishments sincerely john c martin phd chairman chief executive officer gaap diluted earnings per share nongaap diluted earnings per share forwardlooking statement nongaap diluted earnings per share excluded aftertax impact acquisitionrelated expenses aftertax impact restructuring expenses aftertax impact stockbased compensation expenses annual report contains forwardlooking statements regarding clinical studies product candidates including anticipated enrollment completion dates certain clinical trials potential product candidates including anticipated regulatory approvals launches statements predictions involve risks nongaap diluted earnings per share excluded aftertax impact acquisitionrelated expenses aftertax impact restructuring expenses aftertax impact stockbased compensation expenses uncertainties actual results may differ materially please refer gileads annual report year ended december attached report nongaap diluted earnings per share excluded aftertax impact acquisitionrelated expenses aftertax impact restructuring expenses aftertax risks uncertainties affecting gileads business gilead disclaims undertake obligation update revise forwardlooking statements report impact stockbased compensation expenses gilead gileads focus areas hiv aids liver disease three decades first cases hiv aids reported tremendous chronic hepatitis b hepatitis c known silent killers slowly advances treatment transformed terminal disease manageable damage liver many years without causing noticeable symptoms result every chronic condition since approval first hiv medication viread gilead year nearly million people worldwide die complications associated viral played central role development simplified hiv treatment regimens oncedaily infections coformulated medicines available single tablet research shown high adherence hiv medicines critical reducing risk hiv drug resistance treatment failure chronic hepatitis b effectively treated using therapies like viread gileads newest single tablet regimen quad undergoing review regulatory agencies maintains longterm viral suppression also associated reversal liver cirrhosis united states europe united states europe continue support development new commu nitybased awareness campaigns encourage hepatitis b screening linkage care initiated phase studies gs novel prodrug tenofovir active agent gileads recent expansion asia focusing efforts educating community viread gs exhibits greater potency human clinical studies dose ten times lower disease availability effective treatment options viread viread may enable new hiv combinations feasible viread addition also continuing pursue various approaches limit durations therapy hepatitis ongoing preclinical research evaluating new compounds classes hiv molecules b including oral therapies therapeutic vaccines noncatalytic integrase inhibitors inlicensed boehringer ingelheim october patients hepatitis c gilead aims develop effective alloral treatment regimens gilead also engaged earlystage research focused identifying novel agents thera eliminate need interferon injectable medicine associated seri peutic strategies may role play helping eradicate cure hiv infection ous side effects acquisition pharmasset lead compound gs phase clinical trials brings us important step closer achieving goal together existing pipeline hepatitis c compounds exploring combination regimens help us address unmet need effective medications easier take candidate phase phase phase gs nucleotide nsb inhibitor hepatitis c gs ns protease inhibitor hepatitis c gs nsa inhibitor hepatitis c gs ns protease inhibitor hepatitis c gs nonnucleoside nsb inhibitor hepatitis c candidate phase phase phase gs quad integrase single tablet regimen monoclonal antibody liver fibrosis elvitegraviremtricitabinetenofovir disoproxil fumaratecobicistat hiv aids us eu applications submitted gs cobicistat nonnucleoside nsb inhibitor hepatitis c pharmacoenhancer hiv aids gs elvitegravir tlr agonist hepatitis c hepatitis b integrase inhibitor hiv aids gs gs nucleotide reverse transcriptase inhibitor hepatitis b nucleotide reverse transcriptase inhibitor hiv aids colors imagery pages modified gilead cardiovascular metabolic respiratory heart disease remains leading cause death united states around world due infections genetic factors environmental conditions millions people suffer accounting quarter deaths globally gilead focuses developing therapies disorders cause breathing difficulties respiratory diseases often life alleviate symptoms improve quality life outcomes patients serious threatening significantly impair patient quality life seasonal influenza cardiovascular conditions example causes many five million cases severe illness deaths globally every year gilead strong heritage respiratory arena letairis helps improve exercise capacity delays clinical worsening patients pul invented worlds leading oral antiviral treatment prevention influenza monary arterial hypertension pah incurable cardiovascular disease affects tamiflu commercialized roche people worldwide pah lead heart failure left untreated ranexa reduces painful chronic angina attacks patients may return daily activities unlike currently focus providing therapies people cystic fibrosis cf inherited many angina treatments ranexa taken wide range heart medica chronic disease affects pulmonary digestive system impacts tions helping doctors patients develop comprehensive plan managing concurrent people worldwide lungs cf patients particularly susceptible chronic bacterial cardiovascular diseases infection called pseudomonas aeruginosa treated gileads inhaled antibiotic cayston investigating potential treat infections noncf bronchiectasis exploring full potential ranexa therapy heart metabolic disorders another respiratory condition also testing investigational monoclonal antibody launched new study cardiovascular research foundation assess effi efficacy idiopathic pulmonary fibrosis lifethreatening scarring lungs cacy adding ranexa standard therapy patients angina whose coronary arteries known cause remain partially blocked following angioplasty also conducting phase studies determine whether ranexa role play treatment type diabetes candidate phase phase phase aztreonam inhalation solution candidate phase phase phase noncf bronchiectasis ranolazine gs late sodium current inhibitor incomplete revascularization postpci monoclonal antibody idiopathic pulmonary fibrosis ranolazine late sodium current inhibitor type diabetes ranolazinedronedarone fixeddose combination paroxysmal atrial fibrillation marketed products product indication partners oncology inflammation hiv aids atripla hiv aids bristolmyers squibb company efavirenz mgemtricitabine mg us western europe canada tenofovir disoproxil fumarate mg merck co inc rest world significant progress made fight cancer recent years novel targeted therapies designed specifically address individual tumor biology drug complera hiv aids emtricitabinerilpivirinetenofovir resistance easily tolerated urgently needed disoproxil fumarate truvada hiv aids japan tobacco inc improvements understanding cancer genetics allow oncologists define different emtricitabinetenofovir japan types cancer part body occur also specific disoproxil fumarate molecular characteristics drive many cancers show evidence specific emtriva hiv aids japan tobacco inc molecular abnormalities may best treated using targeted approach emtricitabine japan pursuing potential oncology candidates pik delta inhibitor gs viread hiv aids japan tobacco inc currently clinical trials certain forms leukemia lymphoma tenofovir disoproxil fumarate japan testing monoclonal antibody gs determine role combating various malig nancies including myelofibrosis lifethreatening bone marrow disorder pancreatic cancer liver disease colon cancer addition internal discovery efforts partnership viread chronic hepatitis b glaxosmithkline inc yale university established march working identify new molecular tenofovir disoproxil fumarate china japan saudi arabia targets develop novel targeted therapies address cancer based upon unique molecular characteristics also exploring syk inhibitor gs targeted approach hepsera chronic hepatitis b glaxosmithkline inc inflammatory disorders adefovir dipivoxil asia latin america cardiovascular lexiscan coronary vasodilation astellas pharma inc us canada regadenoson injection rapidscan europe select markets letairis pulmonary arterial hypertension glaxosmithkline inc ambrisentan group outside us ranexa chronic angina menarini group ranolazine europe respiratory cayston cystic fibrosis candidate phase phase phase aztreonam inhalation solution gs pik delta inhibitor chronic lymphocytic leukemia tamiflu influenza b f hoffmannla roche ltd oseltamivir phosphate worldwide gs pik delta inhibitor indolent nonhodgkins lymphoma gs monoclonal antibody myelofibrosis macugen neovascular wet agerelated eyetech inc us pegaptanib sodium injection macular degeneration pfizer inc outside us gs monoclonal antibody pancreatic cancer vistide cmv retinitis aids gs cidofovir injection monoclonal antibody colorectal cancer gs ambisome severe fungal infections astellas pharma inc us canada syk inhibitor rheumatoid arthritis amphotericin b liposome injection dainippon sumitomo pharma co ltd japan corporate information focus board directors senior leadership team robert schooley md independent registered public john c martin phd john c martin phd professor medicine head accountants chairman chief executive officer chairman chief executive officer division infectious diseases ernst young llp gilead sciences vice chair department medicine palo alto california john f milligan phd university california san diego james denny president chief operating officer corporate headquarters gilead sciences annual report lead independent director eric j topol md gilead sciences inc gilead sciences board directors norbert w bischofberger phd director scripps translational lakeside drive executive vice president science institute foster city ca usa john f cogan phd research development chief academic officer scripps health senior fellow hoover institution chief scientific officer professor translational genomics wwwgileadcom stanford university scripps research institute gregg h alton vicechairman west wireless stockholder inquiries etienne f davignon executive vice president health institute inquiries stockholders minister state corporate medical affairs potential investors regarding chairman genfina bernard wagner md company always welcome kevin young cbe emeritus research professor receive prompt response please direct carla hills executive vice president pathology new york university requests information chair chief executive officer commercial operations medical center hills company international investor relations consultants kristen metza health policy advisory board gilead sciences inc senior vice president sir richard feachem kbe freng lakeside drive kevin e lofton human resources dscmed phd chairperson foster city ca usa president chief executive officer director global health group catholic health initiatives robin l washington professor global health senior vice president university california san francisco information regarding gilead also john w madigan chief financial officer university california berkeley available wwwgileadcom retired chairman chief executive officer scientific advisory board seth f berkley md stock listing tribune company joel r huff phd chairperson chief executive officer gilead common stock traded retired vice president gavi alliance nasdaq global select stock market gordon e moore phd medicinal chemistry symbol gild retired chairman merck research laboratories michael v drake md chief executive officer chancellor annual meeting intel corporation paul berg phd university california irvine annual meeting stockholders cahill professor held thursday nicholas g moore biochemistry emeritus david gollaher phd may westin retired global chairman stanford university school medicine president chief executive officer san francisco airport hotel pricewaterhousecoopers california healthcare institute francis v chisari md transfer agent registrar richard j whitley md professor virology immunology calvin q pan md communications concerning stock distinguished professor scripps research institute president transfer requirements lost certificates loeb scholar chair pediatrics medical procare pllc changes address professor pediatrics microbiology peter b dervan phd directed transfer agent medicine neurosurgery bren professor chemistry robert shapiro phd university alabama birmingham california institute technology chairman computershare sonecon llc washington boulevard gayle edlund wilson paul e klotman md jersey city nj chair ralph parsons foundation president chief executive officer richard j whitley md usa john e clara b whitmore distinguished professor per woldolsen professor baylor college medicine loeb scholar chair pediatrics wwwcomputersharecom retired president human health professor pediatrics microbiology intercontinental division john w mellors md medicine neurosurgery equal opportunity employer merck co inc professor medicine university alabama birmingham gilead sciences proud equal chief division infectious diseases opportunity employer extends director emeritus gilead sciences university pittsburgh school per woldolsen employment men women board directors medicine retired president human health culturally diverse backgrounds george p shultz phd intercontinental division environment respects individual distinguished fellow eugene r schiff md merck co inc differences recognizes hoover institution leonard miller professor medicine employee integral member stanford university director schiff liver institute corporate secretary company workforce reflects director center liver diseases gregg h alton values celebrates individuals university miami school executive vice president corporate make growing team medicine medical affairs gilead sciences annual report gilead sciences inc lakeside drive foster city california gilead sciences biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need companys mission advance care patients suffering lifethreatening diseases worldwide headquartered foster city california gilead operations north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead sciences gilead logo design hepsera letairis ranexa truvada viread vistide volibris registered trademarks gilead sciences inc one related companies atripla registered trademark bristolmyers squibb gilead sciences llc lexiscan registered trademark astellas us llc tamiflu registered f trademark hoffmannla roche inc macugen registered trademark eyetech inc wwwgileadcom full us prescribing information gilead products available wwwgileadcom focus gilead sciences annual report gilead sciences annual report gilead sciences inc lakeside drive foster city california gilead sciences biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need companys mission advance care patients suffering lifethreatening diseases worldwide headquartered foster city california gilead operations north america europe asia pacific ambisome cayston complera emtriva eviplera gilead gilead sciences gilead logo design hepsera letairis ranexa truvada viread vistide volibris registered trademarks gilead sciences inc one related companies atripla registered trademark bristolmyers squibb gilead sciences llc lexiscan registered trademark astellas us llc tamiflu registered f trademark hoffmannla roche inc macugen registered trademark eyetech inc wwwgileadcom full us prescribing information gilead products available wwwgileadcom